MOOWR for Pharmaceuticals & APIs
MOOWR Scheme — Pharmaceuticals & APIs Manufacturers
Pharma supply chains depend on KSMs and intermediates from China and Europe, with capital-intensive cGMP plants and validated equipment. MOOWR removes the duty drag on both — without exposing exports to the cash-flow distortions of refund cycles.
Typical imported inputs
- Key Starting Materials and intermediates (HSN 2933, 2934, 2941) — BCD 7.5%, IGST 12%
- Solvents and process chemicals (HSN 2905, 2915) — BCD 5%–7.5%
- Glass-lined reactors, centrifuges, lyophilisers (HSN 8419, 8421) — BCD 7.5%, IGST 18%
- HVAC and clean-room modules (HSN 8415, 9406) — BCD 7.5%–10%
- Primary packaging — vials, stoppers, blister foil (HSN 7010, 4011) — BCD 10%
Duty profile
A formulation plant with ₹250 Cr API imports faces a blended 9–11% duty incidence. MOOWR defers this entirely; export shipments to regulated markets (US, EU) carry zero duty cost on the imported KSM portion.
Worked example
| Annual KSM + intermediates imports | ₹200 Cr |
| Annual capital imports (reactors, HVAC) | ₹50 Cr |
| BCD @ 7.5% blended | ₹18.75 Cr |
| IGST @ 16% blended | ₹35.0 Cr |
| Total duty deferred under MOOWR | ₹53.75 Cr |
| Annual interest saving @ 9% | ~₹4.8 Cr |
Why MOOWR fits Pharmaceuticals & APIs
- USFDA / EU-GMP traceability dovetails with Form MOOWR-2 batch-wise records — minimal incremental compliance load.
- Multiple finished forms (tablets, injectables, sterile) can run from the same bonded campus.
- DTA sales for domestic formulations + LUT-based exports — single Customs licence, no scheme-switching.
Case snapshot
A Hyderabad-headquartered API maker with two Maharashtra plants operationalised MOOWR across both sites. Combined annual deferment: ₹38 Cr. Plant 2 capacity expansion was funded entirely by working capital released.
FAQs
Are R&D pilot batches in scope?+
Yes — provided the R&D activity occurs within the bonded premises and the inputs are accounted for in MOOWR-2 records. Wastage from validation runs is treated under standard manufacturing accounting.
How does MOOWR interact with our existing DGFT export incentives?+
RoDTEP and Drawback continue to apply on the export portion. MOOWR addresses the input-side duty deferment; export incentives address the output side.
Model MOOWR on your pharmaceuticals & apis import basket
Send us your top-20 HSN codes, annual import volumes and DTA/export split. Receive a CFO-ready impact memo within 48 hours.